Eli Lilly and Co. (LLY) Declares Quarterly Dividend of $0.51
Eli Lilly and Co. (NYSE:LLY) declared a quarterly dividend on Monday, October 17th. Stockholders of record on Tuesday, November 15th will be paid a dividend of 0.51 per share on Friday, December 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 2.57%.
Shares of Eli Lilly and (NYSE:LLY) traded down 0.96% during trading on Monday, hitting $78.51. 2,250,085 shares of the stock were exchanged. The stock has a market cap of $83.04 billion, a P/E ratio of 33.84 and a beta of 0.17. The stock has a 50-day moving average of $79.73 and a 200 day moving average of $77.79. Eli Lilly and has a 12-month low of $67.88 and a 12-month high of $88.16.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, hitting analysts’ consensus estimates of $0.86. The firm earned $5.40 billion during the quarter, compared to the consensus estimate of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The firm’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.90 earnings per share. Equities analysts predict that Eli Lilly and will post $3.59 earnings per share for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/eli-lilly-and-co-lly-declares-quarterly-dividend-of-0-51.html
In other Eli Lilly and news, insider Donald A. Zakrowski sold 1,213 shares of Eli Lilly and stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $83.16, for a total transaction of $100,873.08. Following the transaction, the insider now owns 1,300 shares of the company’s stock, valued at approximately $108,108. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 240,000 shares of Eli Lilly and stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $82.87, for a total value of $19,888,800.00. Following the transaction, the insider now directly owns 126,020,570 shares in the company, valued at approximately $10,443,324,635.90. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Argent Trust Co boosted its position in Eli Lilly and by 0.3% in the second quarter. Argent Trust Co now owns 4,184 shares of the company’s stock valued at $329,000 after buying an additional 12 shares during the period. Mycio Wealth Partners LLC boosted its position in Eli Lilly and by 1.3% in the second quarter. Mycio Wealth Partners LLC now owns 2,431 shares of the company’s stock valued at $191,000 after buying an additional 32 shares during the period. RiverPoint Capital Management LLC boosted its position in Eli Lilly and by 0.5% in the second quarter. RiverPoint Capital Management LLC now owns 9,434 shares of the company’s stock valued at $743,000 after buying an additional 48 shares during the period. Frontier Wealth Management LLC boosted its position in Eli Lilly and by 0.5% in the second quarter. Frontier Wealth Management LLC now owns 9,933 shares of the company’s stock valued at $782,000 after buying an additional 50 shares during the period. Finally, Banced Corp boosted its position in Eli Lilly and by 3.0% in the second quarter. Banced Corp now owns 3,832 shares of the company’s stock valued at $321,000 after buying an additional 111 shares during the period. 74.99% of the stock is currently owned by institutional investors.
A number of research firms have commented on LLY. Leerink Swann reaffirmed a “buy” rating and issued a $103.00 price objective on shares of Eli Lilly and in a report on Sunday, October 9th. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Wednesday, October 5th. BMO Capital Markets reaffirmed a “buy” rating and issued a $94.00 price objective on shares of Eli Lilly and in a report on Monday, October 3rd. Goldman Sachs Group Inc. raised shares of Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price target for the company from $89.00 to $95.00 in a report on Tuesday, September 27th. Finally, Deutsche Bank AG reissued a “buy” rating on shares of Eli Lilly and in a report on Tuesday, September 20th. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Eli Lilly and presently has an average rating of “Buy” and a consensus price target of $97.06.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.